A missense polymorphism (rs11895564, Ala380Thr) of integrin alpha 6 is associated with the development and progression of papillary thyroid carcinoma in Korean population

Journal of the Korean Surgical Society

Volumn 81, Issue 5, 2011, Pages 308-315

  Kim, Su Kang ^a   Kim, Dong Kwan ^a   Oh, In Hwan ^a   Song, Jeong Yoon ^a   Kwon, Kee Hwan ^a   Choe, Bong Keun ^a   Kim, Yong Ho ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Alpha 6 (ITGA6); Integrins; Papillary thyroid cancer; Polymorphism; Progression

Indexed keywords

EID: 84255170945     PISSN: 12260053     EISSN: 20930488     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;115:3801-3807.
3. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
4. Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, et al. Recent advances in thyroid cancer. Curr Probl Surg 2008;45:156-250. (Pubitemid 351372859)
5. Sturgis EM, Li G. Molecular epidemiology of papillary thyroid cancer: in search of common genetic associations. Thyroid 2009;19:1031-1034.
6. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 2011; 209:139-151.
7. Costa P, Parsons M. New insights into the dynamics of cell adhesions. Int Rev Cell Mol Biol 2010;283:57-91.
8. Mousa SA. Adhesion molecules: potential therapeutic and diagnostic implications. Methods Mol Biol 2010;663: 261-276.
9. Gibson NJ. Cell adhesion molecules in context: CAM function depends on the neighborhood. Cell Adh Migr 2011; 5:48-51.
10. Brabek J, Mierke CT, Rosel D, Vesely P, Fabry B. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal 2010;8:22.
11. Wells A, Chao YL, Grahovac J, Wu Q, Lauffenburger DA. Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci 2011;16:815-837.
12. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-138.
13. Humphries MJ. Integrin structure. Biochem Soc Trans 2000;28:311-339.
14. Cavallaro U, Dejana E. Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol 2011; 12:189-197.
15. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010;9:804-820.
16. Gahmberg CG, Fagerholm SC, Nurmi SM, Chavakis T, Marchesan S, Gronholm M. Regulation of integrin activity and signalling. Biochim Biophys Acta 2009;1790:431-444.
17. Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 2011;71:2417-2422.
18. Salajegheh A, Smith RA, Kasem K, Gopalan V, Nassiri MR, William R, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol 2011;37:93-99.
19. Iuliano R, Palmieri D, He H, Iervolino A, Borbone E, Pallante P, et al. Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocr Relat Cancer 2010;17:1001-1006.
20. Ozgen AG, Karadeniz M, Erdogan M, Berdeli A, Saygili F, Yilmaz C. The (-174) G/C polymorphism in the interleukin- 6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Invest 2009;32:491-494.
21. Erdogan M, Karadeniz M, Ozbek M, Ozgen AG, Berdeli A. Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population. J Endocrinol Invest 2008;31:750-754.
22. Park HJ, Choe BK, Kim SK, Park HK, Kim JW, Chung JH, et al. Association between collagen type XI α 1 gene polymorphisms and papillary thyroid cancer in a Korean population. Experimental and Therapeutic Medicine 2011; 2:1111-1116.
23. Johnatty SE, Beesley J, Chen X, Macgregor S, Duffy DL, Spurdle AB, et al. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet 2010;6:e1001016.
24. Cheng I, Plummer SJ, Neslund-Dudas C, Klein EA, Casey G, Rybicki BA, et al. Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 2010;19:2124-2132.
25. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 2004;89:3713-3720. (Pubitemid 39071462)
26. Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 1999;46:209-216. (Pubitemid 29197769)
27. Kim JY, Jung EJ, Jeong SH, Jeong CY, Ju YT, Lee YJ, et al. Clinical characteristics and prognosis of multifocal papillary thyroid carcinoma. J Korean Surg Soc 2010;79:442-446.
28. Kim JY, Jung EJ, Jeong SH, Jeong CY, Ju YT, Lee YJ, et al. The indices of body size and aggressiveness of papillary thyroid carcinoma. J Korean Surg Soc 2011;80:241-244.
29. Giordano D, Gradoni P, Oretti G, Molina E, Ferri T. Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol 2010;35:118-124.
30. Piersanti M, Ezzat S, Asa SL. Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol 2003;14:183-191. (Pubitemid 37346700)
31. Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 2011;42:500-506.
32. Cañadas Garre M, López de la Torre Casares M, Becerra Massare P, López Nevot MA, Villar Del Moral J, Munoz Perez N, et al. BRAF (T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. Endocrinol Nutr 2011;58:175-184.
33. Pasquali D, Circelli L, Faggiano A, Pancione M, Renzullo A, Elisei R, et al. CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. Eur J Endocrinol 2011;164:397-404.
34. Chen X, Gorlov IP, Merriman KW, Weng SF, Foy M, Keener G, et al. Association of smoking with tumor size at diagnosis in non-small cell lung cancer. Lung Cancer 2011 Jun 4 [Epub]. DOI:10.1016/j.lungcan.2011.04.020.
35. Correa GT, Bandeira GA, Cavalcanti BG, de Carvalho Fraga CA, Dos Santos EP, Silva TF, et al. Association of -308 TNF-a promoter polymorphism with clinical aggressiveness in patients with head and neck squamous cell carcinoma. Oral Oncol 2011;47:888-894.